Frederick Howard to Doxorubicin
This is a "connection" page, showing publications Frederick Howard has written about Doxorubicin.
Connection Strength
0.097
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
Score: 0.052
-
Towards Patient-Specific Optimization of Neoadjuvant Treatment Protocols for Breast Cancer Based on Image-Guided Fluid Dynamics. IEEE Trans Biomed Eng. 2022 11; 69(11):3334-3344.
Score: 0.045